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Mesenchymal stem cells (MSC) are present throughout the body and are thought to play a role 
in tissue regeneration and control of inflammation. MSC can be easily expanded in vitro and 
their potential as a therapeutic option for degenerative and inflammatory disease is therefore 
intensively investigated. Whilst it was initially thought that MSC would replace dysfunctional 
cells and migrate to sites of injury to interact with inflammatory cells, experimental evidence 
indicates that the majority of administered MSC get trapped in capillary networks and have 
a short life span. In this review, we discuss current knowledge on the migratory properties 
of endogenous and exogenous MSC and confer on how culture-induced modifications of 
MSC may affect these properties. Finally, we will discuss how, despite their limited survival, 
administered MSC can bring about their therapeutic effects.
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IntroductIon
Mesenchymal stem cells (MSC) are present in virtually all tissues where they interact with tissue cells 
and, under conditions of inflammation, with immune cells. They have multipotent differentiation 
capacity, which allows them to differentiate in osteoblasts, adipocytes, chondrocytes, and other 
cell types and they have immunomodulatory capacity by sensing and controlling inflammation 
and modifying the proliferation and cytokine production of lymphocytes and myeloid-derived 
immune cells (1). MSC are relatively easy to isolate and expand in culture and therefore have 
prospect as a therapeutic tool in degenerative and autoimmune disease and in transplantation. 
Experimental pre-clinical and clinical studies with MSC are based on the isolation of MSC from 
bone marrow or adipose tissues and the expansion of MSC in vitro. Culture-expanded MSC can be 
administered via different routes, including via intramuscular injections, subcutaneously and via 
intravenous infusion. While it was originally anticipated that MSC could be used for replacement 
of dysfunctional cells via their capacity to differentiate into tissue cells (2), the current paradigm 
is that MSC support resident progenitor cells via paracrine mechanisms (3, 4). Even this idea may 
need refinement as recent studies suggest that MSC may not have a long lifespan after administra-
tion (5, 6). The reason why this may be the case is not clear. A rapid disappearance of MSC raises 
the question of how MSC therapy might work. It is possible that a small fraction of administered 
MSC escapes death and migrates to sites of injury and inflammation and that these MSC bring 
about the beneficial effects of MSC. Another possibility is that MSC are able to rapidly pass on 
their effect to other cells that subsequently mediate tissue repair or immunomodulation. Even the 
clean-up process of MSC itself may be a trigger for the therapeutic effects of MSC. In the present 
review, we discuss recent findings on the life and fate of tissue resident and administered MSC and 
try to link these findings with the regenerative and immunomodulatory effects of MSC.
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MIgratIon of MSc in vitro
It has been shown that MSC migrate in response to many chemo-
tactic factors, like platelet-derived growth factor-AB (PDGF-AB), 
insulin-like growth factor-1 (IGF-1), the chemokines RANTES, 
fluorescent MSC in the blood after the induction of liver damage 
(17), suggesting that systemic signals trigger the release of MSC 
from the bone marrow.
One of the difficulties detecting circulating MSC is that their 
immunophenotype is not necessarily the same as that of culture-
expanded MSC. Several of the markers used for the identification 
of MSC have an adhesion function and their expression is therefore 
likely to be different on non-adherent MSC. Furthermore, although 
the first compartment to search for circulating cells is usually the 
blood stream, a recent report suggests that adipose tissue derived 
MSC may migrate via the lymphatic system (18). It was demon-
strated that MSC can be released by adipose tissue or bone marrow 
in response to inflammation and that they accumulate in lymph 
nodes and blood vessels via CXCL12 (SDF-1)/CXCR4 dependent 
mechanisms (Figure 1A). Finally, one may wonder whether the 
recruitment of MSC from distant sites is required for the control 
of immune responses and initiation of repair in tissues as MSC are 
found locally in all tissues, from skin to brain (13). In case of injury, 
local MSC from tissue or blood vessels need to travel only short 
distances to get to sites of injury and thereby cut the blood stream 
route short (Figure 1B).
Transplanted organs provide a unique opportunity for studying 
the migration of MSC, as MSC can be cultured from tissue biopsies 
and their donor or recipient origin determined by HLA typing. A 
study in heart transplant patients demonstrated that MSC present 
in transplanted hearts were all of donor origin (19). No MSC of 
recipient origin were found, even not many years after transplanta-
tion. Similar data were found in lung transplant patients (20). These 
data suggest that MSC do not migrate between tissues, not even 
under inflammatory conditions as found in transplanted organs. 
At the same time these data demonstrate that MSC can in principle 
survive after transplantation. A major difference, however, between 
these studies and studies that show that MSC are short-lived after 
Key concept 1 | Migration of MSc
MSC express a range of chemokine receptors, allowing them to specifically 
migrate towards chemokine gradients.
macrophage-derived chemokine (MDC), and stromal-derived fac-
tor-1 (SDF-1) (7). Accordingly, MSC express the tyrosine kinase 
receptors for PDGF and IGF, as well as the RANTES and MDC 
receptors CCR2, CCR3, and CCR4, and the SDF-1 receptor CXCR4. 
Most chemokines are more effective on TNFα-primed cells, sug-
gesting that the mobilization of MSC and their subsequent homing 
to injured tissues may depend on the systemic and local inflamma-
tory state (7). Whereas culture-expanded MSC are widely used in 
clinical trials, it is not clear how cultivation and GMP manufactur-
ing processes may influence the homing properties of MSC in vivo. 
However, it has been shown that cell culture duration and the degree 
of cell expansion has a clear impact on MSC morphology, dif-
ferentiation, viability, and migratory properties (8). Furthermore, 
several groups have shown that freshly isolated MSC show supe-
rior homing ability compared to expanded MSC (9, 10) and that 
different MSC subtypes, like classical MSC and multipotent adult 
progenitor cells have different migration potential (11) in in vitro 
migration assays. This suggests that different MSC preparations 
show variation with regard to their homing receptor expression, 
and this may result in differences in their therapeutic effect. Culture 
conditions appear therefore a potent tool in modulating the effect 
of MSC administration.
MIgratIon of EndogEnouS MSc
The study of endogenous MSC migration in vivo is complex. 
MSC are located in the bone marrow, from where they may 
migrate to other sites via mechanisms potentially similar to those 
Key concept 2 | Migration of endogenous MSc
The migration of endogenous MSC is controversial. Hard evidence for the 
migration of MSC via the bloodstream is sparse. As MSC are present in 
virtually all tissues, they may migrate within tissues to sites of injury or 
inflammation.
Key concept 3 | MSc are short-lived after administration
In vitro expanded MSC have a short lifetime after in vivo administration.
Intravenously infused MSC home to the lungs, from where they disappear 
within 24h. Living MSC are not detected at other tissue sites.
exploited by hematopoietic stem cells. However, MSC may be 
resident in peripheral blood, which would make the specific 
identification of migrating MSC difficult. The detection of MSC 
in the circulation is controversial. While some studies showed 
that cord blood and mobilized peripheral blood are enriched for 
MSC (12), others failed to detect MSC in the circulation (13), 
even after stem cell mobilization or in cord blood (14). MSC 
have been detected in peripheral blood in patients with hip bone 
fractures (15), but it can be questioned whether MSC are present 
in the blood of these patients via active recruitment or whether 
mechanical disruption of the bone tissue is responsible for this. 
A study in rat showed that hypoxia induced the mobilization of 
MSC in peripheral blood (16) and a murine study investigating 
the mobilization of fluorescent MSC injected in the bone mar-
row of non-fluorescent animals detected an increased number of 
administration (5) as discussed in the next paragraph, is that MSC 
that are administered as a form of therapy are culture-expanded and 
administered without supporting tissue around them, as is the case 
in organ transplantation. The localization and microenvironment 
that MSC face after transplantation as a cell suspension or embed-
ded in an organ are not comparable and are likely to be responsible 
for the apparent discrepant survival data.
LocaLIzatIon and HoMIng of ExogEnouS MSc
The use of MSC for immunomodulation or regenerative therapy 
in pre-clinical models for autoimmune disease, transplantation, or 
degenerative disease offers the possibility of studying the migration 
of exogenous MSC. Several studies have demonstrated the homing 
of administered MSC to sites of injury (21–23). The migration 
of MSC to such sites may be dependent on chemotactic signals 
derived from injured or inflamed tissues. A study using a model 
of acute kidney injury demonstrated that the migration of MSC 
to the injured kidney is dependent on CD44 expression on MSC 
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FIgure 1 | two potential routes for recruitment of endogenous MSc after 
tissue injury. (A) Cytokines, chemokines, and growth factors like SCF, G-CSF, 
and SDF-1 are released by the injured tissue, which may trigger recruitment of 
MSC from the bone marrow to sites of injury via the circulation. 
(B) Alternatively, MSC are recruited from within tissues to sites of injury via 
migration within the stroma or via micro-capillaries. SCF, stem cell factor; 
G-CSF, granulocyte-colony stimulating factor; SDF-1, stromal cell derived 
factor-1; BM, bone marrow.
(24). The expression of the chemokine receptor CXCR4 on MSC 
also appears to play a role, as overexpression of CXCR4 increases 
the homing of MSC to injured kidneys (25).
The migration of MSC is likely to depend on their route of 
administration. Most studies use the intravenous route and it has 
become clear that a large proportion of MSC that are injected via 
this route are trapped in the lungs upon first passage (5, 10, 23, 26). 
After 24 h MSC are relocated to other organs, in particular the liver 
and also the spleen (5, 27). MSC also reappear at injured tissue sites 
(27). It is however questionable whether MSC that leave the lungs 
are still viable. In our previous work, we demonstrated that MSC 
are no longer viable 24 h after intravenous infusion, but that their 
radioactive label was still detectable in the liver (5). The elimina-
tion of MSC may be dependent of immunological mechanisms, 
which will be discussed below. The potential rapid disappearance 
of infused MSC does not rule out a functional effect of the cells. It 
has for instance been demonstrated that the phagocytosis of dead 
MSC induces the generation of macrophages with a regulatory 
phenotype (28) (Figure 2). It is also possible that a small proportion 
of cells escapes elimination and is responsible for the therapeutic 
effects of MSC.
Evasion of the lung trap may improve the survival of MSC and 
may affect the distribution of the cells after administration. Arterial 
injection may ensure better delivery of MSC to organs of interest. 
MSC injected in the renal arteries are retained in the glomeruli for 
at least several days (29). A study examining the engraftment of 
MSC in the liver concluded that administration via the portal vein 
led to far better engraftment than administration via the vena cava 
(30). While intravenous infusion of MSC for treatment of cardiac 
infarct has been shown long time ago to lead to poor engraftment 
in the ischemic heart, injection of MSC directly in the myocardium 
improves the uptake of cells (26, 31).
It thus appears that MSC are trapped in the first micro capillary 
network they encounter. The question is why this is the case and 
whether the entrapment of MSC in such networks perhaps con-
tributes to in particular the immunomodulatory effects of MSC 
treatment?
EffEct of cuLturE on tHE MIgratIon and SurvIvaL of 
MSc
Mesenchymal stem cells cultures are routinely obtained by adher-
ence of MSC to plastic culture flasks and propagation of the cells 
in medium containing 10–15% fetal calf serum (32). However, 
culture affects the phenotype of MSC. Various studies show that 
surface markers of freshly isolated MSC differ from those of cul-
tured MSCs. It has for instance been described that adipose tis-
sue derived MSC are contained in the CD34+ cell fraction of the 
Key concept 4 | culture affects the phenotype of MSc
Culture medium and plastic adherence have a major impact on the phenotype 
of MSC. The size of MSC dramatically increases in culture and the expression 
of adhesion molecules is strongly up regulated. This affects the distribution 
of MSC after administration.
stromal vascular fraction, but CD34 expression is lost during MSC 
cell expansion in culture (33). Recently, Braun et al. (34) showed 
that upon activation in culture, MSC upregulate CD105, CD146, 
and CD271 and propose that this upregulation is required for 
improved motility and attachment to the plastic. In accordance 
with this hypothesis, we as well as other groups have observed 
a change in MSC morphology during early culture phase. Over 
time, small round-shaped cells change into large spindle shaped 
cells (34, 35) and cultured MSC become around 20 μm in diameter 
(36, 37). Since this diameter is larger than the size of pulmonary 
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micro-capillaries, it is not surprising that after intravenous infu-
sion of MSC the majority of the cells are trapped in the lungs (5, 
37). Furthermore, the modulated expression of cell adhesion and 
chemoattraction molecules on cultured MSC may account for a 
different migratory behavior of cultured MSC compared to non-
cultured MSC. The shortevity of MSC after infusion may also have 
a relation with the culture-induced changes in MSC phenotype. 
We and others have demonstrated that activated NK cells can lyse 
culture-expanded MSC of not only allogeneic but also autologous 
origin (38, 39), suggesting that culture may induce changes in MSC 
that makes them targets for NK cells. Cultured MSC may also 
appear foreign for macrophages, and trigger a clean-up response 
after administration, which may result in an immunosuppressive 
effect as discussed above (28). These data indicate that it is not 
unlikely that at least some of the effects observed upon administra-
tion of MSC depend on MSC properties acquired during culture 
expansion.
How doES MSc tHErapy work?
Series of observations on the migration, distribution, and survival of 
MSC after administration contrast with the original ideas on the life 
and fate of MSC and make it hard to understand how MSC therapy 
works. In the 1960s, cells with osteogenic differentiation capacity 
were identified in the bone marrow by Friedenstein and colleagues 
(40). Later it was shown that in addition to osteogenic differentia-
tion, these cells, MSC, were able to undergo adipogenic, chondro-
genic, and myogenic differentiation (41). As a logic consequence it 
was believed that MSC could be expanded in culture, administered 
and that they would engraft and differentiate into functional cells. 
Some of the early trials with MSC that took place in osteogenesis 
imperfecta patients were based on this idea (42). It turned out, 
FIgure 3 | proposed model of MSc contribution to immune suppression 
and tissue repair. Intravenous administration of culture-expanded MSC 
(violet cells) leads to modulation of the function of endogenous MSC  
(red cells) and macrophages via the secretome of the administered cells  
(e.g., TGF-β, PGE-2, and other factors) and phagocytosis of MSC by 
macrophages. The activation of resident MSC and induction of regulatory 
macrophages induces tissue regeneration. MSC furthermore induce 
regulatory T cells via different mechanisms, including the secretion of TGF-β 
and an indirect elevation of IL2. Administration of MSC also elicits a systemic 
immune response, which triggers an immunosuppressive response.
FIgure 2 | proposed mechanism of action of intravenously injected 
cultured MSc. Administered culture-expanded MSC (large violet cells) target 
immune cells, including macrophages, and resident progenitor cells, including 
MSC (small red cells) via their secretome (e.g., TGF-β, PGE-2, and other 
factors) to stimulate immunomodulatory and regenerative processes. In 
addition, phagocytosis of MSC by macrophages may induce the formation of 
regulatory macrophages. TGF-β, transforming growth factor-β; PGE-2, 
prostaglandin E2.
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however, that culture-expanded MSC show little engraftment and it 
is proposed that the secretion of trophic factors and immunomodu-
latory cytokines and chemokines by MSC are at the base of the 
therapeutic effects (43, 44). However, the accumulation of MSC in 
the lungs after intravenous infusion, their short survival time and 
limited distribution to other sites suggests that MSC rapidly pass 
on their effect to resident cells, which may subsequently mediate 
the immunomodulatory and regenerative effect induced by MSC 
administration. This idea is summarized in Figure 3.
Regulatory T cells are one of the cell types that may bring the 
effects of MSC forward. MSC have been demonstrated to be able 
to induce regulatory T cells (45, 46). The mechanisms of MSC-
induced regulatory T cell induction depend on local conditions. 
MSC constitutively secrete TGF-β, which acts as a growth factor for 
regulatory T cells (45), and under inflammatory conditions MSC 
express IDO, which plays a role in the generation of regulatory T 
cells (47). MSC induce de novo regulatory T cells by increasing levels 
of IL2, which occurs when activated T cells are inhibited by MSC 
in their proliferation but not in their activation (46). Furthermore, 
monocytes are identified as a crucial intermediate cell type after 
MSC-induced differentiation in type 2 macrophages. Type 2 mac-
rophages produce IL10 and CCL18, which trigger the induction of 
regulatory T cells. Type 2 macrophages can furthermore be induced 
by prostaglandin E2 secretion by MSC (48) and themselves play a 
role in resolving inflammation and mediating tissue repair (49). 
It was recently demonstrated that the reparative effect of MSC 
injected in infarcted myocardium was partially mediated via type 
2 macrophages as depletion of these macrophages attenuated the 
MSC effect (50).
As infused MSC are around only for a short time, their induc-
tion of cells with regulatory phenotypes via the secretion of soluble 
factors has to occur hastily. It is also possible that MSC trigger 
responses by other cells merely by their presence. We recently dem-
onstrated that MSC induce a systemic inflammatory response 
within hours after infusion (51). Whether this response triggers the 
induction of regulatory cells and whether it originates from MSC or 
from resident tissue and/or immune cells remains to be identified. 
effect or whether the bulk dead cells are responsible for this we 
cannot conclude about at this moment. There is evidence that dead 
MSC reappear in the liver (5), and interestingly, macrophages that 
phagocytized dead MSC have been shown to obtain a regulatory 
function (28).
Taking all published data into considering, we have to acknowl-
edge that we yet know little about how MSC therapy works. Further 
studies aimed at exploring MSC fate and functional properties after 
administration will have to shine light on this and allow the design 
of effective MSC therapy.
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